Zacks Research Estimates ResMed’s FY2025 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Zacks Research boosted their FY2025 EPS estimates for shares of ResMed in a research note issued to investors on Thursday, March 13th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $9.37 per share for the year, up from their previous estimate of $9.36. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.41 EPS, Q1 2026 earnings at $2.31 EPS, Q2 2026 earnings at $2.41 EPS, FY2026 earnings at $9.71 EPS and Q1 2027 earnings at $2.51 EPS.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%.

A number of other analysts have also recently issued reports on RMD. Citigroup upgraded ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. boosted their price objective on ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. The Goldman Sachs Group assumed coverage on ResMed in a research note on Thursday, January 16th. They issued a “buy” rating on the stock. Piper Sandler increased their target price on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Finally, KeyCorp increased their target price on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ResMed has a consensus rating of “Moderate Buy” and a consensus target price of $243.82.

ResMed Stock Performance

Shares of NYSE RMD opened at $220.07 on Monday. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $235.76 and its two-hundred day moving average is $239.49. The company has a market cap of $32.32 billion, a P/E ratio of 25.98, a P/E/G ratio of 1.53 and a beta of 0.74. ResMed has a 12 month low of $172.19 and a 12 month high of $263.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. True Wealth Design LLC increased its position in ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 110 shares in the last quarter. Colonial Trust Co SC increased its position in ResMed by 6,250.0% in the 4th quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 125 shares in the last quarter. Optiver Holding B.V. bought a new stake in ResMed in the 4th quarter valued at about $33,000. Itau Unibanco Holding S.A. increased its position in ResMed by 1,000.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 150 shares in the last quarter. Finally, OFI Invest Asset Management bought a new stake in ResMed in the 4th quarter valued at about $39,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the sale, the director now owns 77,218 shares of the company’s stock, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kaushik Ghoshal sold 9,113 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total value of $2,145,200.20. Following the sale, the insider now directly owns 9,725 shares in the company, valued at approximately $2,289,265. This trade represents a 48.38 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,940 shares of company stock worth $9,164,385. Insiders own 0.71% of the company’s stock.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.96%. ResMed’s payout ratio is 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.